MedTrace Logo

The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy

NCT02231788 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2020-01-31

No results posted yet for this study

Summary

The Efficacy of a Fixed Dose Combination of Telmisartan/S-Amlodipine on 24-hour Ambulatory BP Control Compared with Telmisartan Monotherapy

Conditions

Interventions

DRUG

Telminuvo®Tab. 40/2.5mg

Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg

DRUG

Telmitrend®Tab. 80mg

Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Hyo-Soo Kim, Professor · Seoul University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02231788 on ClinicalTrials.gov